INBRAIN Neuroelectronics has signed a know-how collaboration agreement with Mayo Clinic to accelerate the development and commercialization of its graphene-based brain-computer interface therapeutics (BCI-Tx). Business Wire
Key points:
-
They will evaluate the BCI-Tx platform in IRB-approved settings for neurological disorders. Business Wire
-
INBRAIN is opening a U.S. subsidiary, starting with a Boston office, while keeping global headquarters and R&D in Barcelona. Business Wire
-
As part of their growth, they are scaling manufacturing of the graphene-based BCI and broadening therapeutic applications beyond Parkinson’s disease. Business Wire
-
To date, INBRAIN has raised USD 124 million from a global syndicate including Aliath Bioventures. Business Wire
Read the full post here: